1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Novartis Looks To Expand Beovu’s Use And Move On From Safety Scare

Diabetic Macular Edema (DME) Filing Possible In 2021

 
• By Andrew McConaghie

New data for a further indication should help Novartis rebuild momentum for competitor to Eylea, but safety concerns could take years to overcome.

Basel, Switzerland - 27 August, 2016: sign on the wall of a Novartis building. Novartis International AG is a Swiss pharmaceutical company based in Basel, Switzerland.
Forecasts for Beovu have been downgraded after the safety concerns emerged in February

Novartis AG’s Beovu has matched market-leading ophthalmic therapy Eylea in a new Phase III study, part of its efforts to establish the new less frequently dosed therapy.

The topline results from a Phase III non-inferiority study should pave the way for Beovu (brolucizumab) to add diabetic macular...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Taiho’s Oral, Mutation-Agnostic DMD Candidate Misses Phase III Endpoint

 
• By Lisa Takagi

The oral, twice-daily candidate was expected to control decline in motor function in DMD patients regardless of their gene mutations.

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

More from R&D

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 
• By Alaric DeArment

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

BREAKING NEWS: Merck & Co. Leaps Into COPD Space With $10bn Verona Buy

 
• By Kevin Grogan

The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.